natgillin/translations-raw huggingface dataset:
A pharmaceutical composition according to claim 9 for use in treating a disorder associated with CRM1 activity. The pharmaceutical composition for use according to claim 10, wherein: the disorder is selected from a proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, and a respiratory disorder; 
Spoj prema bilo kojem od zahtjeva 1 do 6, ili njegova farmaceutski prihvatljiva sol, solvat ili hidrat, ili farmaceutski sastav prema zahtjevu 7 za uporabu u liječenju poremećaja odabranog od proliferativnog poremećaja, upalnog poremećaja, autoimunog poremećaja, virusne infekcije, oftamološkog poremećaja, neurodegenerativnog poremećaja, poremećaja abnormalnog rasta tkiva, poremećaja vezanog uz unos hrane, alergija i poremećaja disanja.
reacting an intermediate of formula (II) with an appropriate carboxaldehyde of formula (VI) with the formation of a compound of formula (I), wherein t is 1, herein referred to as compounds of formula (I-c), or 
ROB pri čemu su varijable kako je definirano u zahtjevul; d) reakciju međuprodukta formule (II) odgovarajućim karboksaldehidom formule (VI) uz stvaranje spoja formule (I), pri čemu t je 1, ovdje se nazivaju spojevi formule (I-c), s =
R7a is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocyclyl; 
a je izabran iz grupe koja se sastoji od izborno supstituiranog alkila, izborno supstituiranog alkenila, izborno supstituiranog alkinila, izborno supstituiranog heteroalkila, izborno supstituiranog arila, izborno supstituiranog heteroarila, izborno supstituiranog cikloalkila i izborno supstituiranog heterociklila;
The ophthalmic formulation of claim 5, wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of nepafenac, meloxicam, diclofenac, bendazac, ketorolac, oxyphenbutazone, bromfenac, flurbiprofen, pranoprofen, surprofen, indomethacin, and a pharmaceutically acceptable salt thereof. 
Oftalmička formulacija prema bilo kojem od zahtjeva 5-7, koja nadalje sadrži ne-steroidni anti-upalni lijek odabran iz skupine koja se sastoji od nepafenaka, meloksikama, diklofenaka, bendazaka, ketorolaka, oksifenbutazona, bromfenaka, flurbiprofena, pranoprofena, surprofena, indometacina, te njihovih farmaceutski prihvatljivih soli.
The operator will thus have a visual indication of state of spray. 
Time će operator imati vizualni podatak o stanju raspršivanja.
Preferably, the catalyst (N-cat) is selected from the group consisting of acetic acid, formic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, HCl, HBr, H2SO4, H3PO4, BCl3, BF3OEt2, MgCl2, MgBr2, AlCl3, ZnCl2, Cu(BF4)2, aluminosilicates, acidic ion exchange resins, carbon treated with HCl, H2SO4 or HNO3, and mixtures thereof; 
Postupak prema zahtjevu 1, naznačen time da je katalizator (N-kat.) odabran iz skupine koja se sastoji od octene kiseline, mravlje kiseline, trifluoroctene kiseline, metansulfonske kiseline, p-toluolsulfonske kiseline, HCI, HBr, H2SO4, HaPO4, BCLb, BF:0Et, MgCl, MgBr,, AICI;, ZnCL, Cu(BF;),, aluminosilikata, kiselih smola ionskih izmjenjivača sa HCI, H2SO, ili HNO; tretiranim ugljikom i njihovih mješavina.
Ar3 is as defined for Ar2; and 
Ar? je definiran kao za Ar; i
A compound for use according to any one of claims 3 to 6 wherein the compound is for administration with an effective amount of a vaccine which is effective in protecting avians against protozoal infestations. 
Spoj prema za uporabu prema bilo kojem od zahtjeva 3 do 6, naznačen time, da se spoj primjenjuje s učinkovitom količinom cjepiva koje je djelotvorno za zaštitu ptica protiv protozoalnih zaraza,
The combined organic layers dried (Na2SO4), filtered and concentrated to give intermediate 11 as a brown solid (0.4668 g, 86%). 
Kombinirani organski slojevi su sušeni (Na,SOy), filtrirani i koncentrirani da bi se dobio Intermedijer 11 kao smeđe čvrsta supstanca (0.4668 g, 86%).
wherein R1 is as defined for the compound of formula (II), with a chiral amine of formula (V) 
OH uso PH gdje je RI kao što je definiran za formulu (II), s kiralnim aminom formule (V)
The method according to claim 8 wherein the cardiovascular diseases derived from heart rhythm disorders are chosen among auricular and/or ventricular arrhythmia, tachycardia, fibrillation and/or electrical conduction defects induced by myocardial infarction. The method according to claim 11 wherein the cardiovascular disease derived from heart rhythm disorders is sudden death. Docosahexaenoic acid ester with panthenol. 
Ester dokosaheksanske kiseline prema patentnom zahtjevu 1 ili 2, piridin-3-ilmetil dokosaheksanoat ili farmaceutski pripravak prema patentnom zahtjevu 8, naznačen time da je za upotrebu prema patentnom zahtjevu 10, pri čemu su kardiovaskularne bolesti izvedene od poremećaja ritma srca sljedeće: aurikularna i/ili ventrikularna aritmija, tahikardija, fibrilacija i/ili poremećaj električne vodljivosti induciran infarktom miokarda.
The Cladribine pharmaceutical formulation for use or the use according to any of the preceding claims wherein the pharmaceutical formulation is to be administered in combination with interferon-beta. 
Kladribinska farmaceutska formulacija, namijenjena upotrebi, ili upotreba, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što farmaceutsku formulaciju treba primijeniti u kombinaciji s interferonom-B.
When the marking/identification is applied only to a section of the surface of a product, subsequent examination of that particular surface is required to determine the presence or absence of the marking/identification. 
Mineralna vuna kao proizvod u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što se UV- ili IR-aktivna komponenta nalazi na najmanje jednom dijelu površine proizvoda.
The method as claimed in claim 17 wherein the second IOP reducing agent is selected from the group comprising: B-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, rho-kinase inhibitors, a2 agonists, miotics, neuroprotectants, A3 antagonists, A2A agonists, ion channel modulators and combinations thereof. 
Tvar za uporabu u skladu s patentnim zahtjevom 6, pri čemu je drugi agens za snižavanje IOP odabran iz grupe koja se sastoji od f-blokatora, analoga prostaglandina, inhibitora karboanhidraze, inhibitora rho kinaze, a, agonista, miotika, neuroprotektanata, A3 antagonista, A,A agonista, modulatora ionskog kanala i njihovih kombinacija.
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja kada je ispitivan u komparativnoj kliničkoj studiji je bioekvivalentan sa komercijalnim proizvodom OxyContinTM, Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja sadrži 10 mg oksikodon hidroklorida kada je ispitivan u komparativnoj kliničkoj studiji je sa referentnom tabletom koja sadrži 10 mg oksikodon hidroklorida u matričnoj formulaciji koja sadrži: a) "Oksikodon hidroklorid: 10.0 mg/tableta b) Laktozu (osušena raspršivanjem): 69.25 mg/tableta c) Povidon: 5.0 mg/tableta d) Eudragit* RS 30D (krutina): 10.0 mg/tableta
grinding mixture obtained in step iv), and vi) compressing mixture obtained in step v). 
V) mljevenje smjese dobivene u koraku iv), i vi) sabijanje smjese dobivene u koraku v).
The resulting solid (4.068 g) was suspended in water (40 ml), filtered (to remove any traces of urea) and purified by FCC on reversed phase LiChroprep RP-18 (40-63 micron). 
Nastala krutina (4.068 g) je suspendirana u vodi (40 mL), filtrirana (da se uklone tragovi ureje) i čišćena pomoću FCC na reverznoj fazi LiChroprep RP-18 (40-63 mikrona).
The method according to claim 17, wherein the compound is a pharmaceutically acceptable salt form. 
Farmaceutski prihvatljiva sol prema zahtjevima 24, 28 ili 30, naznačena time da je farmaceutski prihvatljiva sol, sol toluensulfonske kiseline.
According to a third aspect of the invention there is provided a method of connecting to a preferred network at a communication device, the method comprising: providing notification to a central server relating to a change in the current location for the communication device; receiving a subscriber network identifier for a preferred network from the central server on the basis of the current location, if the central server has determined that the communication device is not connected to the preferred network; and disconnecting from a current network connection and reconnecting to the preferred network using the receive subscriber network identifier. 
Postupak za povezivanje komunikacionog uređaja na željenu mrežu, pri čemu taj postupak obuhvaća: HR P20141037 T1 osiguravanje obavještavanja centralnom serveru (108) koje se odnosi na promjenu trenutne lokacije komunikacionog uređaja; prijem pretplatničke mrežne identifikacije koja je osigurana postupkom prema bilo kom od zahtjeva 1 do 15, ukoliko je centralni server odredio da komunikacioni uređaj nije povezan na najpoželjniju mrežu; i isključivanje sa trenutne mrežne konekcije i ponovno povezivanje na poželjnu mrežu koristeći primljenu pretplatničku mrežnu identifikaciju.
A compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents a1; 
U) naznačen time što Het predstavlja heterocikličku skupinu s jednim atomom dušika, na kojeg je B izravno vezan, te s 4 do 7 atoma ugljika, gdje je navedena heterociklička skupina nesupstituirana ili je supstituirana s 1 do 4 supstituenti, koje se neovisno bira iz skupine koju čine supstituenti a;
with a compound of formula (R1)(R2)M-N3 (II b), wherein R1 and R2, independently of one another, represent an organic residue and M is aluminum or boron; and isolating the resulting compound of formula (VII′). 
sa spojem formule (R,)(R2)M-N; (IT b), gdje R; i Ro, neovisno jedan od drugoga, predstavljaju organski ostatak i M je aluminij ili bor; te izolaciju rezultirajućeg spoja formule (VII).
Number of different CDR3: 346. 
(87) Broj međunarodne objave:
The polypeptide of claim 1 wherein the polypeptide elicits a protective immune response in a mammalian host against strains of C.difficile. 
Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što polipeptid postiže zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
The process according to claim 3 wherein R1 and R2 are each ethyl, the copper halide is CuCl, the ligand is 1,10-phenanthroline, the base in step i) is Cs2CO3, and the base in step ii) is K2CO3. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što svaki od R1 i R2 je etil, bakreni halogenid je CuCl, ligand je 1,10-fenantrolin, baza u koraku i) je Cs2CO3, a baza u koraku ii) je K2CO3.
The process of claim 37, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing. 
Oblik doziranja sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 22, naznačen time da je opioidni analgetik odabran iz skupine koja sadrži kodein, morfin, oksikodon, hidrokodon, hidromorfon, ili oksimorfon ili njihove farmaceutski prihvatljive soli, hidrati i solvati, te bilo koje smjese prethodno navedenih analgetika.
A multi-armed polymer prodrug of claim 2, wherein said prodrug, when evaluated in a suitable animal model for solid tumor-type cancers and administered in a therapeutically effective amount, is effective to suppress tumor growth to an extent that is at least twice that observed for the unmodified anticancer agent when similarly administered over a time course of 30 days. 
Višestruko razgranati polimerni prolijek iz patentnog zahtjeva 2, pri čemu je navedeni prolijek, procijenjen na odgovarajućem životinjskom modelu za karcinome čvrstog tipa 1 primijenjen u terapijski učinkovitoj količini, učinkovit za supresiju rasta tumora do razmjera koji je najmanje dvostruki od promatranog za nemodificirani agens protiv raka, koji je primijenjen na sličan način tijekom 30 dana.
It is also known that this type of steel requires significant additions of chromium and phosphorous, especially the first mentioned element in order to increase the steel capacity of being hardened and to enhance the production of carbides, whereas the second mentioned element is added to make ferrite harder and cause the yield point to raise. 
Također je poznato da ovaj tip čelika zahtjeva značajna dodavanja kroma 1 fosfora, posebno prvog navedenog elementa da bi se povećao kapacitet čelika da bude stvrdnut i da bi se povećala proizvodnja karbida, pri čemu se drugi navedeni element dodaje da bi se ferit napravio tvrđim i radi povećanja granice elastičnosti.
A valve as claimed in claim 3, wherein, in the saline position, the saline inlet (220) is connected to the outlet (230) via the primary channel (310) and not connected to the secondary channel (320). 
Ventil u skladu s patentnim zahtjevom 3, pri čemu je u položaju za fiziološku otopinu, dovod (220) fiziološke otopine povezan s izlazom (230) preko primarnog kanala (310) i nije povezan sa sekundarnim kanalom (320).
According to one preferred embodiment of the inventive process, the calcium carbonate is first contacted with the at least one acid having a pKa of less than or equal to 2.5 and after 30% of the total amount of said at least one acid having a pKa of less than or equal to 2.5 have been added, the calcium carbonate is contacted with the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid. 
Postupak prema zahtjevu 10, naznačen time da se kalcijev karbonat prvo dovodi u kontakt sa najmanje jednom kiselinom koja ima pK, od manje od ili jednako 2.5 i nakon što je dodano 80 % ukupne količine navedene najmanje jedne kiseline koja ima pK, od manje od ili jednako 2.5, kalcijev karbonat se dovođi u kontakt sa barem jednom u vodi topivom ne-polimernom organskom i/ili anorganskom slabom kiselinom i/ili vodikovom soli navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline.
In accordance with an embodiment of the present invention, such a search space is fixedly defined in the specification of the communication system. 
Naprava za prijem sukladno jednom od zahtjeva 5 1li 6, naznačena time da je prostor pretraživanja konfiguriran u podatkovnom predjelu podokvira silazne veze.
The operation of the feed sensor switch 116 has been described above. When the feed sensor end switch 116 is activated, indicating that material is backing up at the top of the conveyor 52, preferably the control circuit 198 merely shuts down the operation of the motor 118 and feed conveyor 92 . 
Sušilica prema patentnom zahtjevu 8 još obuhvaća 1 krajnji prekidač (116) senzora dovoda postavljen na drugi dio kraja kućišta dovodnog transportera za detektiranje kada je prethodno utvrđena kvaliteta materijala akumulirana na gornjem kraju sredstva za transportiranje između prve i druge beskonačne trake (52, 54).
the electrochemical charge (µEq/g) of the aqueous medium before the addition of the cPCC. 
elektrokemijskog naboja (mEq/g) vodenog medija prije dodavanja cPCC.
The preferred embodiment, the enantiomer trans-(lR)-N-methyl-4-phenyl-1,2,3,4-tetrahydro-l-naphthalenamine and its pharmaceutically acceptable acid addition salts, exhibits excellent synaptosomal norepinephrine uptake blocking activity. 
Poželjna realizacija, enantiomer trans-(1R)-N-metil-4-fenil-1,2,3,4-tetrahidro-1-naftalinamina i njegove farmaceuiski prihvatljive aditivne soli s kiselinama, pokazuju sjajnu aktivnost za blokiranje potrošnje sinaptosomalnog norepinefrina.
Another embodiment of the invention comprises a compound of Formula I and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time što sadrži spoj prema zahtjevu 1 i farmaceutski prihvatljiv nosač.
As shown in Figure 17, aggregates will have diameters distributed around this mean. 
Kako je prikazano na Slici 17, agregati će imati promjere raspodijeljene oko ovog srednjeg.
In another aspect described herein, a compound of Formula 7 is nitrated using a mixture of sulfuric acid, nitric acid and methylene chloride. 
koji obuhvaća nitriranje spoja koji ima formulu 7 upotrebom smjese sumporne kiseline i dušične kiseline u prisutnosti diklorometana o PG
For determination of the inhibition of uptake ten concentrations of drugs covering 6 decades are used. 
Za određivanje inhibicije apsorpcije upotrijebljeno je deset koncentracija lijekova koji pokrivaju 6 dekada.
The compound, or a pharmaceutically acceptable salt thereof according to claim 3, wherein R4a is a phenyl group substituted by a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, or a halo-lower alkoxy group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group. A compound represented by the following formula: 
Spoj u skladu s patentnim zahtjevom 3, ili njegova farmaceutski prihvatljiva sol, gdje R* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-C;.4 alkilnom skupinom, Ci.4 alkoksi skupinom ili halogen-C;.4 alkoksi skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom ili C;.4 alkoksi skupinom.
"thioether", as used herein, pertains to a -SR group, wherein R is a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group; 
"tioeter", kako se ovdje koristi, odnosi se na -SR skupinu, pri čemu R je Ci; alkilna skupina, C3.20 heterociklilna skupina, ili C5. arilna skupina;
The method according to any one of claims 1 to 4, characterised by an X-ray powder diffraction pattern, made using CuKa1 radiation, which comprises peaks at degrees 2Θ (±0.1 degrees 2Θ) as follows: Θ [°] d-value [Å] 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time, da ima karakterističan uzorak difrakcije praha X-zraka, koji se dobiva uporabom CuKa1-radijacije, i koji obuhvaća vršne vrijednosti u stupnjevima 2θ (± 0,1 stupanj 2θ), kako slijedi:
More preferably, the protein is an Interferon. Preferably, the Interferon is an Interferon-B. Another object of the present invention is a container containing a liquid pharmaceutical composition ready for injection and containing a protein as active ingredient, characterised by comprising a closure means coated by an inert fluorinated material. 
Spremnik za tekući farmaceutski pripravak, te navedeni spremnik sadrži tekući farmaceutski pripravak spreman za ubrizgavanje, te kao aktivni sastojak sadrži interferon-f5, naznačen time da sadrži sredstva za zatvaranje obložena inertnim fluoriranim materijalom, te time da je unutarnja površina spremnika obložena sa inertnim materijalom.
The recombinant RhCMV or HCMV vector of any one of claims 1-3, comprising a deletion of US2, US3, US6 or US11 or a homolog thereof, in particular comprising a deletion of Rh158-166 or a homolog thereof. 
Rekombinantni vektor RhCMY ili HCMY u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što sadrži deleciju US2, US3, US6 ili USII ili njihovih homologa, a osobito što sadrži deleciju Rh158-166 ili njegovog homologa.
The duration of said method is often less than 5 hours such as a duration of less than 3 hours, and preferably the duration is less than 2 hours such as a duration of less than 1 hour, and more preferably a duration of less than 30 minutes. 
- > čestice u suspenziji imaju prosječnu veličinu od manje od 60 nm kao što je manje od 50 nm i poželjno manje od 40 nm kao stoje manje od 30 nm, te čak još poželjnije manje od 20 nm, naznačen time da postupak dodatno sadrži
Cocoa-derived material according to claim 1 or 2, wherein the weight ratio of soluble cocoa powder to cocoa extract in said material is comprised between 2:1 and 1:2, and preferably is 1. 
Tvar dobivena iz kakaa u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je omjer mase topljivog praška kakaa prema masi ekstrakta kakaa u dotičnoj tvari u rasponu omjera od 2:1 do 1:2, a poželjno je 1.
is an 8- to 10-membered heteroaryl group containing 1 or 2 heteroatoms independently chosen from N, O, and S, wherein J2 is optionally substituted with one or more substituents independently chosen from amino, cyano, hydroxyl, halogen, C1-C4alkyl, C1-C4alkoxy, mono- and di- C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; 
je 8- do 10-člana heteroaril grupa koja sadrži 1 do 2 heteroatoma neovisno izabrana iz N, O, i S, pri čemu je J2 opcionalno susptituiran s jednim ili više supstituenata neovisno izabranih iz amino, cijano, hidroksil, halogen, C1-C4 alkil, C1-C4 alkoksi, mono-i di- C1-C4 alkilamino, C1-C2 haloalkil, i C1-C2haloalkoksi;
The lipid particle of claim 7, wherein the particle further comprises a non-cationic lipid, preferably wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol, preferably wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof. 
Čestica lipida u skladu s patentnim zahtjevom 5, naznačena time, da čestica nadalje sadrži ne-kationski lipid, poželjno odabran iz skupine koja se sastoji od fosfolipida, kolesterola ili kolesterol derivata, ili smjese fosfolipida i kolesterola ili kolesterol derivata, pri čemu fosfolipid poželjno sadrži dipalmitoilfosfatidilkolin (DPPC), distearoilfosfatidil-kolin (DSPO), ili njihovu smjesu.
The peptide of claim 13, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:69. 
Himerni peptid sukladno zahtjevu 1, naznačen time što se sastoji od SEQ ID NO:69.
The formulation according to any one of the previous claims, wherein the lyophilized formulation has ≥ 95% monomeric antibody. 
3. < Formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što liofilizirana formulacija sadrži > 95% monomernog protutijela.